首页> 外文期刊>The biochemical journal >Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine
【24h】

Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine

机译:过氧化物酶体增殖物激活受体α和δ在肝和小肠的纤维状和脂肪酸介导的编码肝脂肪酸结合蛋白的基因的诱导中的差异参与

获取原文
       

摘要

pLiver fatty-acid-binding protein (L-FABP) is a cytoplasmic polypeptide that binds with strong affinity especially to long-chain fatty acids (LCFAs). It is highly expressed in both the liver and small intestine, where it is thought to have an essential role in the control of the cellular fatty acid (FA) flux. Because expression of the gene encoding L-FABP is increased by both fibrate hypolipidaemic drugs and LCFAs, it seems to be under the control of transcription factors, termed peroxisome-proliferator-activated receptors (PPARs), activated by fibrate or FAs. However, the precise molecular mechanism by which these regulations take place remain to be fully substantiated. Using transfection assays, we found that the different PPAR subtypes (α, γ and δ) are able to mediate the up-regulation by FAs of the gene encoding L-FABP iin vitro/i. Through analysis of LCFA- and fibrate-mediated effects on L-FABP mRNA levels in wild-type and PPARα-null mice, we have found that PPARα in the intestine does not constitute a dominant regulator of L-FABP gene expression, in contrast with what is known in the liver. Only the PPARδ/α agonist GW2433 is able to up-regulate the gene encoding L-FABP in the intestine of PPARα-null mice. These findings demonstrate that PPARδ can act as a fibrate/FA-activated receptor in tissues in which it is highly expressed and that L-FABP is a PPARδ target gene in the small intestine. We propose that PPARδ contributes to metabolic adaptation of the small intestine to changes in the lipid content of the diet./p
机译:肝脏脂肪酸结合蛋白(L-FABP)是一种胞质多肽,具有很强的亲和力,尤其是与长链脂肪酸(LCFA)结合。它在肝脏和小肠中都高度表达,认为在控制细胞脂肪酸(FA)流量中起着至关重要的作用。由于纤维状降血脂药和LCFA都增加了编码L-FABP的基因的表达,因此它似乎处于被纤维状或FAs激活的称为过氧化物酶体增殖物激活受体(PPAR)的转录因子的控制之下。但是,通过这些法规进行精确的分子机理研究仍需充分证实。通过转染试验,我们发现不同的PPAR亚型(α,γ和δ)能够介导FAs体外编码L-FABP的基因的上调。通过分析LCFA和贝特类药物介导的对野生型和PPARα-null小鼠L-FABP mRNA水平的影响,我们发现肠道中的PPARα并不构成L-FABP基因表达的主要调节因子,与肝脏中已知的东西。仅PPARδ/α激动剂GW2433能够在无PPARα的小鼠肠中上调编码L-FABP的基因。这些发现表明,PPARδ可以在其中高度表达的组织中作为纤维状/ FA激活的受体,并且L-FABP是小肠中的PPARδ靶基因。我们认为PPARδ有助于小肠的代谢适应饮食中脂质含量的变化。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号